Stay updated on Ixazomib Citrate for Relapsed Myeloma Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page.

Latest updates to the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a new 'Locations' section with subsections for Arizona, Florida, and Minnesota, consolidating site information under 'Locations'. Removed the separate 'Arizona Locations', 'Florida Locations', and 'Minnesota Locations' entries and updated the page revision to v3.3.3.SummaryDifference0.3%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedPublications note is now described as automatically filled from PubMed, and the Revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check43 days agoChange DetectedRemoved a government funding status notice banner from the page; this is a minor administrative change that does not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check65 days agoChange DetectedNo significant changes detected between the two screenshots. The page content and structure appear unchanged, continuing to present the Study Details for NCT01415882.SummaryDifference0.2%

- Check87 days agoChange DetectedCore content updated to inform users about funding-related operating status and current NIH Clinical Center openness; version updated from v3.1.0 to v3.2.0.SummaryDifference2%

- Check94 days agoChange Detected- Added revision tag v3.1.0 and removed the Plasma cell myeloma resource from the Genetic and Rare Diseases Information Center list. Overall: minor content update with a resource removal.SummaryDifference0.3%

Stay in the know with updates to Ixazomib Citrate for Relapsed Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page.